This finding gave rise to the notion that targeting both of these pathways through the RANKL/RANK/TRAF6 axis could be a practical approach toward improvement in high-grade osteoporosis patients and also help develop novel targeted therapies. This evidence concerns the gene TRAF6 and osteoporosis.